Viimeisimmät kokeilut

EudraCT Number: 2020-003146-36 Sponsor Protocol Number: RIAlta-1 Start Date: 2023-11-15
Sponsor Name: Vall d'Hebron Research Institute (VHIR)
Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
Medical condition: Pulmonary and extrapulmonary tuberculosis
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-003804-15 Sponsor Protocol Number: SGMCBM Start Date: 2023-11-09
Sponsor Name: Leiden University Medical Center
Full Title: A FEASIBILITY STUDY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF COLORECTAL BRAIN METASTASES
Medical condition: Colorectal brain metastases
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055093 Brain cancer metastatic PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001632-28 Sponsor Protocol Number: GENTLE Start Date: 2023-10-24
Sponsor Name: Rijnstate
Full Title: Ghrelin in anterior circulation stroke and EVT
Medical condition: acute ischemic stroke
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003318-35 Sponsor Protocol Number: VX22-264-101 Start Date: 2023-09-25
Sponsor Name: Vertex Pharmaceuticals Incorporated
Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
Medical condition: Type 1 Diabetes Mellitus
Disease: Version SOC Term Classification Code Term Level
20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001287-10 Sponsor Protocol Number: NBK241/2/2022 Start Date: 2023-09-22
Sponsor Name: Gdański Uniwersytet Medyczny
Full Title: Treatment of acute ischemic stroke due to occlusion of a large vessel by mechanical thrombectomy in patients with unknown onset or not meeting the criteria for CT eligibility (ASPECTS
Medical condition: acute ischemic stroke caused by occlusion of a large vessel
Disease: Version SOC Term Classification Code Term Level
23.1 10029205 - Nervous system disorders 10084836 Malignant ischemic stroke LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-004078-53 Sponsor Protocol Number: 83403 Start Date: 2023-08-22
Sponsor Name: Academic Medical Center (AMC), department of Internal Medicine
Full Title: Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping
Medical condition: - Plaque characteristics - Systemic inflammation
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-003063-26 Sponsor Protocol Number: 1634 Start Date: 2023-08-10
Sponsor Name: European Organisation for Research and Treatment of
Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)
Medical condition: Newly Diagnosed Medulloblastoma
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: AT (Ongoing) DE (Ongoing) IT (Ongoing) NL (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001063-27 Sponsor Protocol Number: JZP385-202-01 Start Date: 2023-07-19
Sponsor Name: Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.
Full Title: A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Seve...
Medical condition: Parkinson’s Disease
Disease: Version SOC Term Classification Code Term Level
20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002788-30 Sponsor Protocol Number: IMVT-1401-3202 Start Date: 2023-07-13
Sponsor Name: Immunovant Sciences, GmbH
Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Medical condition: Thyroid Eye Disease (TED)
Disease: Version SOC Term Classification Code Term Level
23.1 100000004853 10084358 Thyroid eye disease LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) BE (Ongoing) LV (Ongoing) HU (Ongoing) SK (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-004917-10 Sponsor Protocol Number: TIGER Start Date: 2023-06-29
Sponsor Name: King's College London [...] 1. King's College London 2. King's College Hospital NHS Foundation Trust
Full Title: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-gro...
Medical condition: Submacular haemorrhage secondary to exudative age-related macular degeneration
Disease: Version SOC Term Classification Code Term Level
20.0 100000004853 10075718 Exudative age-related macular degeneration LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Trial now transitioned)
Trial results: (No results available)

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot